FDA Accepts Application for Bevacizumab Biosimilar
The FDA has accepted a biologics license application for the proposed bevacizumab biosimilar SB8.
Related Articles
Perioperative Pembrolizumab Wins Canadian Approval for Resectable NSCLC
Health Canada has approved perioperative pembrolizumab for resectable non–small cell lung cancer.
First-of-Its-Kind Supportive Oncology Program Offers Unique Training Opportunity for Fellows
The Christie NHS Foundation Trust has created a supportive oncology program to train fellows and offer services for patients living with cancer.
Ponatinib-Based Regimens Strengthen the Ph+ ALL Treatment Paradigm: With Mark B. Geyer, MD, and Elias Jabbour, MD
Drs Geyer and Jabbour discuss ponatinib in Ph+ ALL, data with this agent plus blinatumomab, and how the safety profile of ponatinib affects its use.
Hematologic Oncology Field Sees Almost 20 FDA Approvals in 2024
The movement of CAR T-cell therapy to earlier lines of therapy was among many notable advancements greenlit by the FDA in the hematologic space in…
Zilovertamab Vedotin Produces Activity in Heavily Pretreated R/R Mantle Cell Lymphoma
Zilovertamab vedotin generated responses and was safe in heavily pretreated relapsed/refractory mantle cell lymphoma.
Nivolumab Plus Chemo Shows Long-Term OS Benefit in Chinese Patients With Advanced Gastric, GEJ, or Esophageal Cancer
Nivolumab plus chemotherapy demonstrated long-term survival benefits in advanced gastric, GEJ, or esophageal cancer in China.
Maintenance Galinpepimut-S Appears Effective and Safe in AML in Second CR
Galinpepimut-S demonstrated early efficacy signals in patients with acute myeloid leukemia in second complete remission or later.
Tagitanlimab Plus Chemotherapy Receives Chinese Approval for Recurrent/Metastatic Nasopharyngeal Cancer
Tagitanlimab received marketing authorization from the Chinese NMPA for use with cisplatin and gemcitabine for patients with recurrent or metastatic NPC.
SHR-A1811 Maintains Efficacy, Safety in Pretreated HER2-Expressing/-Mutated Breast Cancer, Other Solid Tumors
An additional 1-year of follow-up confirmed the safety and activity of SHR-A1811 in HER2-expressing or -mutant solid tumors, including breast cancer.
IO-202 Plus Azacitidine Could Bring Long-Awaited Change in HMA-Naive CMML
Gabriel Mannis, MD, discusses the observed clinical activity and manageable safety profile of IO-202 combined with azacitidine in CMML.